---
layout: default
title: Deferasirox
parent: 僅模型預測 (L5)
nav_order: 114
evidence_level: L5
indication_count: 5
---

# Deferasirox
{: .fs-9 }

證據等級: **L5** | 預測適應症: **5** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Deferasirox: From Iron Overload to HIV Infectious Disease

## One-Sentence Summary

Deferasirox is an oral iron chelator originally used to manage chronic iron overload (e.g., transfusional iron overload in thalassemia and myelodysplastic syndromes). The TxGNN model predicts it may also be effective for **HIV infectious disease**, with a **99.40% prediction score**, though this direction is currently supported only by **2 mechanistic/preclinical publications** and **no registered clinical trials**.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Chronic iron overload (iron chelation therapy) — *inferred from drug class and repurposing rationale; not explicitly populated in `original_indications`* |
| Predicted New Indication | HIV infectious disease |
| TxGNN Prediction Score | 99.40% |
| Evidence Level | L4 |
| Taiwan Market Status | ✗ Not marketed (未上市) |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available (flagged as a High-severity data gap, DG002). Based on known information, deferasirox belongs to the iron chelator class, and its efficacy in reducing chronic iron overload is well established; mechanistically it may be applicable to HIV infectious disease through iron-restriction pathways.

The proposed link is indirect but biologically plausible: free intracellular iron promotes oligomerization of the HIV-1 Tat protein and enhances LTR (long terminal repeat) transactivation, a step required for viral replication. In vitro work suggests that restricting endolysosomal/cytosolic iron — which is exactly what an iron chelator like deferasirox does — could dampen this Tat-driven transcriptional activation.

Importantly, this evidence is mechanistic and in vitro only. There is no direct clinical or preclinical antiviral efficacy data for deferasirox in HIV infection, and no drug-specific pharmacokinetic or dosing rationale for this population has been established.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

| PMID | Year | Type | Journal | Key Findings |
|------|-----|------|------|---------|
| [34550543](https://pubmed.ncbi.nlm.nih.gov/34550543/) | 2021 | Mechanistic/In vitro study | Journal of NeuroVirology | Endolysosomal iron restriction reduces HIV-1 Tat oligomerization and LTR transactivation, suggesting iron chelation could limit Tat-driven viral transcription |
| [16529348](https://pubmed.ncbi.nlm.nih.gov/16529348/) | 2006 | Review (new drug bulletin) | Journal of the American Pharmacists Association | General "new drugs" bulletin covering deferasirox alongside unrelated agents (ramelteon, tipranavir, nepafenac); not a study of deferasirox in HIV specifically |

---

## Taiwan Market Information

Deferasirox is **not currently marketed in Taiwan** — 0 authorizations are on record in the evidence pack. TFDA package insert and license data have not yet been retrieved (see Blocking data gap DG001 below).

---

## Safety Considerations

Please refer to the package insert for safety information. Key warnings, contraindications, and drug-drug interaction data have not yet been retrieved from TFDA sources (Blocking data gap DG001) — this must be resolved before any safety-stage (S1) evaluation can proceed.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The HIV indication rests on a single indirect in vitro mechanistic study with no supporting clinical trials, preclinical antiviral data, or drug-specific safety information — consistent with the pack's own L4/S1 "Research Question" classification. The four other TxGNN-predicted indications for deferasirox (chronic hepatitis C, a rare neurodevelopmental disorder, an obsolete hyperlipidemia term, and dermatofibrosarcoma protuberans) are weaker still (L4–L5, S0–S1) and are already flagged Hold or Research Question internally.

**To proceed, the following is needed:**
- TFDA package insert (warnings, contraindications, DDI) — Blocking gap DG001
- Confirmed mechanism of action data for deferasirox — High-priority gap DG002
- In vivo or clinical evidence that iron chelation affects HIV viral load/replication (current support is limited to one in vitro LTR-transactivation study)
- A registered clinical trial or investigator-initiated study before advancing past the Research Question stage
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

